Table 4b.

Overview of enhanced data collection for strategic subgroups of the HCV Research UK cohort

Subgroup	N (% of full cohort)	Additional data collected
Participants taking part in the NHS England early access programme	806 (7.9%)	Data on : 1) routine laboratory results collected annually; 2) prospective health resource utilisation data*; 3) viral sequencing on baseline, during-therapy and post-therapy samples; 4) host genotyping for ∼800,000 single nucleotide polymorphisms
Genotype 3 infected participants taking part in STOP-HCV	∼2000 (19.6%)	Data on : 1)host genotyping for ∼800,000 single nucleotide polymorphisms
Participants in the STOP-HCV cirrhosis sub-study	∼1200 (11.8%)	Data on : 1) routine laboratory results collected annually; 2) viral sequencing on baseline samples; and 3) host genotyping for ∼800,000 single nucleotide polymorphisms

*Refers to data on all HCV-related clinic visits; treatment of adverse effects from antivirals; and general hospital admissions.